MyMD Pharmaceuticals Enrolls First Individual in Phase 2 Clinical Trial of MYMD-1 as a Treatment for Delaying Aging as well as Expanding Healthy Life Expectancy

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals (” MyMD” or “the Company”), a medical phase pharmaceutical business dedicated to prolonging healthy and balanced life expectancy, today announced that the first person has been signed up in the Firm’s Stage 2 scientific trial of lead candidate MYMD-1, an oral immune regulator medication, as a treatment for delaying aging as well as increasing healthy lifespan.

The main endpoint for the Stage 2 double-blind, placebo-controlled professional trial is to achieve a decrease in the distributing degrees of (TNF-α), lump death variable receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the proteins in the body that create inflammation and assist activate the procedure of aging. The second measures of the test will be the safety, tolerability, as well as pharmacokinetics in this population of clients.

” In a Phase 1 medical trial of MYMD-1, we showed the medication’s statistically considerable efficacy in decreasing degrees of TNF-α, a principal in causing pathological aging, in the blood. The FDA has approved TNF-α reduction as the main endpoint for our Phase 2 research, which we believe settings us well for a successful Stage 2 outcome,” said Chris Chapman, M.D., Head Of State, Supervisor and also Chief Medical Officer of MyMD. “The initiation of person enrollment in this research study developments our mission to reduce the aging procedure, avoid loss of muscle mass cells in aging, limit frailty, as well as extend healthy and balanced life-span.”

MyMD has actually mentioned that there are no FDA-approved medications for treating aging disorders and expanding healthy and balanced life expectancy human beings, a market expected to be at least $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are one of the most proposed medications by income, an international market of around $40 billion per year,2 and also, according to Nature Aging journal,3 a slowdown in aging that would certainly enhance life expectancy by one year is worth $38 trillion and also by 10 years is worth $367 trillion.

In addition to aging, MYMD-1’s unique activity in managing the immune system as well as treating chronic inflammation is being created for the treatment of autoimmune illness, consisting of rheumatoid joint inflammation (RA), several sclerosis (MS), diabetic issues, and also inflammatory digestive tract illness.

” We plan to start creating methods for a Stage 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The increasing prevalence of rheumatoid joint inflammation as well as various other autoimmune and inflammatory illness are driving need for TNF inhibitors like MYMD-1, and also our team believe our orally provided medication with really low toxicity would certainly be disruptive to the $60 billion market for RA if approved by the FDA for this indication.”

Rheumatoid arthritis influences around 40 million people worldwide.4.

About MYMD-1.

Initially created for autoimmune conditions, MYMD-1’s primary purpose is to reduce the aging procedure, protect against sarcopenia and frailty, as well as prolong healthy life expectancy. Because it can go across the blood-brain obstacle as well as get to the main nerve system (CNS), MYMD-1 is also positioned to be a feasible treatment for brain-related disorders. Its device of action and also effectiveness in diseases including multiple sclerosis (MS) and thyroiditis have been studied via collaborations with a number of scholastic organizations. MYMD-1 is also showing promise in pre-clinical research studies as a possible therapy for blog post- COVID-19 difficulties and also as an anti-fibrotic and anti-proliferation restorative.

MYMD-1 has revealed efficiency in pre-clinical researches in controling the immune system by doing as a careful prevention of lump necrosis factor-alpha (TNF-α), a chauffeur of chronic swelling. Unlike other therapies, MYMD-1 has been displayed in these pre-clinical researches to selectively obstruct TNF-α when it becomes overactivated in autoimmune conditions and cytokine storms, yet not obstruct it from doing its regular task of being an initial responder to any kind of routine type of modest infection. MYMD-1’s ease of dental dosing is one more differentiator contrasted to currently available TNF-α blockers, every one of which need delivery by shot or infusion. No accepted TNF prevention has actually ever been dosed by mouth. Furthermore, the medication is not immunosuppressive and also has actually not been shown to trigger the significant side effects common with typical treatments that deal with swelling.

About MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical firm dedicated to prolonging healthy and balanced lifespan, is concentrated on creating two unique restorative systems that treat the root causes of disease rather than only attending to the signs. MYMD-1 is a drug system based upon a professional stage tiny molecule that manages the immune system to manage TNF-α, which drives persistent inflammation, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, increase durability, as well as deal with autoimmune conditions and COVID-19- linked clinical depression. The Business’s 2nd medication system, Supera-CBD, is being developed to deal with persistent pain, dependency and also epilepsy. Supera-CBD is a novel artificial by-product of cannabidiol (CBD) as well as is being developed to deal with and surpass the quickly expanding CBD market, which includes both FDA approved medications as well as CBD products not presently regulated as medicines. To learn more, check out www.mymd.com.

Comments are closed.